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Abstract 21 
Background 22 
Lymphatic filariasis (LF) and podoconiosis are neglected tropical diseases (NTDs) that pose a 23 
significant physical, social and economic burden to endemic communities. Patients affected by the 24 
clinical conditions of LF (lymphoedema and hydrocoele) and podoconiosis (lymphoedema) need 25 
access to morbidity management and disability prevention (MMDP) services. Clear estimates of the 26 
number and location of these patients are essential to the efficient and equitable implementation of 27 
MMDP services for both diseases.  28 
 29 
Methodology/Principle findings 30 
A community-based cross-sectional study was conducted in Ethiopia using the Health 31 
Extension Worker (HEW) network to identify all cases of lymphoedema and hydrocoele in 20 woredas 32 
(districts) co-endemic for LF and podoconiosis.  A total of 612 trained HEWs and 40 supervisors from 33 
20 districts identified 26,123 cases of clinical morbidity. Of these, 24,908 (95.3%) reported cases had 34 
leg lymphoedema only, 751 (2.9%) had hydrocoele, 387 (1.5%) had both leg lymphoedema and 35 
hydrocoele, and 77 (0.3%) cases had breast lymphoedema. Of those reporting leg lymphoedema, 36 
89.3% reported bilateral lymphoedema. Older age groups were more likely to have a severe stage of 37 
disease, have bilateral lymphoedema and to have experienced an acute attack in the last six months.  38 
 39 
Conclusions/Significance 40 
This study represents the first community-wide, integrated clinical case mapping of both LF 41 
and podoconiosis in Ethiopia. It highlights the high number of cases, particularly of leg lymphoedema 42 
that could be attributed to either of these diseases. This key clinical information will assist and guide 43 
the allocation of resources to where they are needed most.   44 
 3 
Author Summary 45 
Patients affected by the clinical conditions of lymphatic filariasis (lymphoedema and 46 
hydrocoele) and podoconiosis (lymphoedema) require access to a minimum package of care to 47 
prevent progression of the disease, and to improve their quality of life. Clear estimates of the number 48 
and location of these patients is essential for the delivery of this care. To address this, a community-49 
based cross-sectional study was conducted in Ethiopia using the Health Extension Worker (HEW) 50 
network to identify all cases of lymphoedema and hydrocoele in 20 co-endemic woredas (districts). A 51 
total of 26,123 cases of clinical morbidity were identified. Of these, 24,908 (95.3%) had leg 52 
lymphoedema, of which 89.3% were bilateral. The results of this study will help assist the Neglected 53 
Tropical Disease (NTD) programme at the Federal Ministry of Health (FMOH) in Ethiopia to effectively 54 
and equitably plan the delivery of a basic package of care to those suffering from the clinical 55 
manifestations of both diseases. 56 
 57 
Introduction 58 
Lymphatic filariasis (LF) and podoconiosis are neglected tropical diseases (NTDs) that affect 59 
the world’s poorest people and pose a significant economic burden to developing countries [1]. 60 
Responsible for 90% of cases worldwide, Wuchereria bancrofti is the causative agent of LF in Africa, 61 
and is transmitted through the bite of an infected mosquito. Infection with W. bancrofti can be either 62 
asymptomatic, or present as both acute and chronic clinical conditions. However, the main clinical 63 
conditions of LF disease that are recognised as significant public health priorities include acute 64 
dermatolymphangioadenitis (commonly known as acute attacks), lymphoedema and hydrocoele [2]. 65 
More than 36 million people worldwide are thought to be disfigured and incapacitated by this disease, 66 
leaving them vulnerable to an extremely complex range of physical, social and economic hardships [3, 67 
4].  68 
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Podoconiosis, unlike LF, is not due to an infectious agent but rather is the result of specific 69 
inflammatory reactions to irritant mineral particles acquired from red clay soils derived from volcanic 70 
deposits [5-7]. Specifically, greater quantities of smectite, mica and quartz within the soil have been 71 
shown to have positive associations with podoconiosis prevalence [8]. It is found in highland tropical 72 
areas of Africa, Central America and north-west India where there is commonly a high seasonal rainfall 73 
[5, 6]. It is often termed “non-filarial” lymphoedema, and can be generally clinically distinguished from 74 
LF lymphoedema by its ascending progression of disease (rather than descending), and by being most 75 
commonly bilateral, as compared with LF which is most commonly descending and unilateral [7, 9]. 76 
As with LF, stigmatisation is a common and serious problem for those affected by podoconiosis, with 77 
patients experiencing suicidal thoughts, dissolution of marriage plans, often receiving insults and 78 
being excluded at social events [10]. Further, the economic consequences of the limb condition are 79 
profound, with productivity losses per patient amounting to 45% of working days per year, causing a 80 
monetary loss equivalent to US$ 63 per annum [11].  81 
The World Health Assembly (WHA) adopted Resolution 50.29 in 1997, encouraging Member 82 
States to eliminate LF as a public health problem [12]. Soon after, the World Health Organisation 83 
(WHO) launched the Global Programme to Eliminate LF (GPELF) with a target date for achieving 84 
elimination by 2020. The two component strategies of GPELF are to a) interrupt transmission through 85 
mass drug administration (MDA), and b) to manage morbidity and prevent disability (MMDP) among 86 
those affected by the clinical manifestations of the disease. Although no global target has yet been set 87 
for the elimination of podoconiosis [7], strategies aimed at its control can be divided into primary, 88 
secondary and tertiary interventions. Primary intervention includes the use of footwear, regular foot 89 
hygiene and the application of floor coverings to reduce the contact between feet and the irritant soil. 90 
Secondary and tertiary interventions focus on the management of the lymphoedema-related 91 
morbidity and include wound care, exercise, elevation of the legs, treatment of acute attacks and 92 
providing psychosocial and socio-economic support to those affected [7].  93 
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As the minimum package of care for managing the lymphoedema seen in LF and podoconiosis 94 
patients to manage morbidity is very similar, it is practical that MMDP should be integrated to help 95 
improve cost-effectiveness and extend the reach of the programme [2]. This is particularly important 96 
in Ethiopia where there is a high burden of both diseases, with 29 of the 70 LF-endemic districts 97 
considered to be co-endemic [13, 14]. However, before MMDP activities for both diseases can be 98 
implemented, better patient estimates and an understanding of the co-distributions of both diseases 99 
at district level are vital. To assist the NTD programme at the Federal Ministry of Health (FMOH) to 100 
effectively and equitably plan the delivery of a basic package of care to those suffering from clinical 101 
manifestations of both diseases, we have examined the clinical burden of lymphoedema and 102 
hydrocoele in 20 co-endemic woredas (districts) of Ethiopia.  103 
 104 
Methods 105 
Ethics statement 106 
Ethical approval for this study was obtained from the Research Ethics Committee at the Liverpool 107 
School of Tropical Medicine, UK (Research Protocol 12.22), and the Amhara and SNNP Regional Health 108 
Bureaus in Ethiopia. Informed consent was obtained from all household heads and patients involved 109 
in the study. All adult participants provided informed consent, no children participated in the study. 110 
Participants who could read and write provided written consent. Those who could not read and write, 111 
had the consent information read to them and oral consent was recorded. The methods of collecting 112 
oral and written consent was approved by the Regional Health Bureau ethical committees.  113 
 114 
Study site characteristics 115 
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The study was conducted in the Southern Nations, Nationalities, and Peoples’ region (SNNPR) 116 
and Amhara region of Ethiopia (Fig 1) between May and August 2015. In total 20 districts were 117 
selected; 14 districts from eight zones in the SNNPR, and six districts from three zones in Amhara 118 
region, which had a total population of 3,075,318 (50.2% male) [15, 16].  119 
 120 
Fig 1. Study regions in Ethiopia, and the number and prevalence per 10,000 of lymphoedema and 121 
hydrocoele cases by district. A. Lymphoedema – all cases. B. Lymphoedema – all prevalence. C. 122 
Lymphoedema – bilateral cases. D. Lymphoedema – bilateral prevalence. E. Lymphoedema – 123 
unilateral cases. F. Lymphoedema – unilateral prevalence. G. Hydrocoele – all cases. H. Hydrocoele – 124 
all prevalence.  125 
Note. The names of each district and their endemicity classification are shown in reference S1 Fig. 126 
 127 
S1. Fig. Map highlighting district names and endemicity status  128 
 129 
At the time of the study, the 20 districts were considered to be co-endemic for LF and 130 
podoconiosis, with LF prevalence based on mapping conducted using immunochromatographic card 131 
tests (ICT; Alere, Scarborough, ME, USA) to detect the presence of circulating W. bancrofti antigen as 132 
per the WHO protocol [17-19]. However, due to borderline endemicity in districts, which had exactly 133 
the 1% prevalence threshold for endemicity, a subsequent ‘re-mapping’ validation was undertaken in 134 
nine of these 20 districts before the scale-up of MDA [14]. These nine districts were: Bensa, Saula 135 
Town (Sawla), Kebena, South Ari (Debub Ari), Guanga (Guangua), Ebinat, Fogera, Simada (Semada) 136 
and E/Enawga (Inarj-Inawuga). This ‘re-mapping’ resulted in seven of these districts being reclassified 137 
as non-endemic, while two (South Ari and Simada), have remained endemic. The name and 138 
distribution of the non-endemic and endemic districts are shown in S1 Fig [14]. With regards to the 139 
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clinical burden of disease, prior to the present study, no comprehensive information was available on 140 
the number of clinical cases in these districts, and no available service provision for MMDP of 141 
lymphoedema and hydrocoele. Before 2015, LF MDA had been initiated in only two of the 20 districts, 142 
Bero district and Guraferda district of the Bench Maji zone. This MDA was integrated with the 143 
onchocerciasis control programme.  144 
  145 
Study design and tools 146 
The community-based cross-sectional study was conducted using the Health Extension 147 
Worker (HEW) network to identify cases. HEWs are predominately female, and are recruited from the 148 
communities they serve to expand access to basic health promotion, disease prevention and selected 149 
curative health services [20]. The HEWs searched for patients affected by LF and podoconiosis in their 150 
community catchment areas, with two HEWs covering a population of approximately 5,000 people 151 
[20]. Generally, two HEWs are assigned to cover one kebele. The HEWs used a patient information 152 
collection form (translated into Amharic) to record personal details including general demographic 153 
information (sex, age, occupation, rural/urban residence, education level), and the condition of the 154 
patient (leg lymphoedema only, breast lymphoedema, hydrocoele or ‘both’ leg lymphoedema and 155 
hydrocoele), and whether leg lymphoedema was unilateral or bilateral. Patients were also asked 156 
whether they had suffered an acute attack in the past six months because of their swelling or 157 
lymphoedema.  158 
The severity of leg lymphoedema was staged as mild, moderate or severe using WHO 159 
recommended guidelines [21]. Patients with mild lymphoedema were categorised as those with a 160 
slight, soft swelling; whilst moderate lymphoedema was an enlarged swelling with shallow folds; and 161 
severe lymphoedema being greatly enlarged, with deep folds, and skin changes including mossy 162 
lesions and nodules. HEWs were given an image of the three stages of lymphoedema to assist them 163 
in recording the staging. Due to the sensitivity of the condition, HEWs were not asked to stage or 164 
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confirm the presence of the hydrocoele, but just asked to record the men reporting scrotal swelling. 165 
HEWs were not asked to differentiate between the causes of lymphoedema (podoconiosis or  166 
lymphatic filariasis) as currently podoconiosis is a diagnosis of clinical exclusion based on history, 167 
physical examination and certain disease-specific tests to exclude common differential diagnoses [18]. 168 
The use of such a complex clinical algorithm, previously used in epidemiological mapping of LF and 169 
podoconiosis in Ethiopia [18] was considered inappropriate for community-based health worker 170 
patient searching. 171 
 172 
Training  173 
In each district, all HEWs and two supervisors attended a one-day training session. The training 174 
focused on: a) how to identify lymphoedema and hydrocoele; b) how to classify lymphoedema into 175 
the three stages; and c) how to record the patient information on the collection form. In addition, all 176 
attendees were trained on morbidity management (basic care package) for LF and podoconiosis to 177 
enable HEWs to give advice at the time of identification regarding basic lymphoedema management, 178 
or to refer any suspected hydrocoele cases to their nearest health facility for validation and further 179 
referral for surgery. 180 
 181 
Data collection and analysis 182 
Following the training, each HEW returned to her respective catchment area to identify all 183 
cases of lymphoedema and hydrocoele through house-to-house patient searching; with the two 184 
supervisors overseeing the data collection and acting as a point of contact if any problems were 185 
encountered. The two HEWs assigned to each kebele as per the standard government health system, 186 
were assigned to identify patients in the households they usually serve. For each kebele, the HEWs 187 
used the list of households available in each kebele to prevent overlap between the HEWs and to 188 
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ensure all households were covered. During the data collection, each HEW wrote the name of each 189 
household head on the data collection form, and this was cross-checked against the list of households 190 
by the trained supervisors. To ensure no households were missed, HEWs sought support from the 191 
Health Development Army (volunteer community health promoters) and the kebele administrative 192 
team to inform each specific household of the date and time the HEW would visit the household for  193 
the patient searching. The supervisors also visited a selection of the households to ensure they had 194 
been visited by the HEWs.  195 
The assessment was completed within ten days in most of the districts, with the data 196 
collection forms collated soon afterwards. All data was entered into Microsoft Excel Version 12.3.6 197 
(Microsoft Corp., Redmond, VA, USA) and analysed using IBM SPSS Statistics 32 (IBM Corp., Armonk, 198 
NY, USA).  Prevalence estimates (per total 10,000 population) were calculated using the 2015 199 
population estimates as the denominator, which were calculated from the 2007 census [15] using the 200 
annual growth rates [16].  201 
Statistical analysis between regions and variables including condition, severity of 202 
lymphoedema, acute attacks, sex and age were examined using Pearson’s chi square with p value 203 
<0.05, and/or odds ratios (OR) with 95% confidence intervals (95%CIs) to determine levels of 204 
significance. Maps highlighting the study regions, and the number and prevalence of cases with 205 
lymphoedema and hydrocoele per 10,000 of the total population were produced using geographical 206 
information system (GIS) software ArcGIS 10 (ESRI., Redlands, CA, USA). Further overall, lymphoedema 207 
and hydrocoele prevalence rates were compared between the newly classified non-endemic districts 208 
and the endemic districts.  In addition, to account for the different geographical sizes of the districts 209 
and to better understand the density of conditions, the number of cases per square kilometre (km2) 210 
was calculated and presented in a supplementary file.   211 
 212 
Results 213 
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Summary of reported cases 214 
A total of 612 HEWs and 40 supervisors from 20 districts were trained to collect and report 215 
case data. Table 1 presents the number of cases reported per clinical condition for each region, zone 216 
and district.  A total of 26,123 cases (48% male; mean age 43.6 years) were reported. For the SNNPR, 217 
the total cases was 17,285 cases (44.6% male; mean age 51.2 years) and for Amhara region was 8,838 218 
cases (54.8% male; mean age 43.8 years). Overall, the majority of cases were either subsistence 219 
farmers (n=17,243; 66%) or housewives (n=5,557; 21.3%), had permanently lived in the rural setting 220 
(n=24,198; 92.6%), had not attended school and were illiterate (n=21,631; 82.8%)  221 
 222 
Table 1. Reported number and prevalence (per 10,000 of the total population) of clinical cases.223 
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Region Zone  # District 
Total 
population 
Leg lymphoedema 
only 
Hydrocoele  
only 
Both  
conditions** 
Breast lymphoedema 
only 
Total 
N Prevalence  N Prevalence*  N Prevalence  N Prevalence  N Prevalence  
SNNPR 
Siliti 
1 Lanfuro 142,581 1,781 124.9 20 1.4 3 0.2 1 0.1 1,805 126.6 
2 Sankura 104,051 1,130 108.6 23 2.2 17 1.6 0 0.0 1,170 112.4 
Sidama 
3 Hawela Tula 152,844 405 26.5 4 0.3 1 0.1 0 0.0 410 26.8 
4 Bensa ǂ 307,878 1,882 61.1 54 1.8 29 0.9 2 0.1 1,967 63.9 
Gedeo 5 Yirga Chefe 239,763 1,699 70.9 57 2.4 13 0.5 0 0.0 1,769 73.8 
Wollaita 6 Sodo zuria 199,775 2,564 128.3 12 0.6 5 0.3 0 0.0 2,581 129.2 
GamoGofa 
7 Boreda 83,451 1,078 129.2 14 1.7 6 0.7 25 3.0 1,123 134.6 
8 Gezegofa 84,298 1,343 159.3 11 1.3 32 3.8 2 0.2 1,388 164.7 
9 Oyida 40,903 624 152.6 7 1.7 18 4.4 0 0.0 649 158.7 
10 Saula Town ǂ 27,879 247 88.6 1 0.4 0 0.0 0 0.0 248 89.0 
Gurage 11 Kebena ǂ 64,318 892 138.7 29 4.5 10 1.6 0 0.0 931 144.7 
Bench Maji 
12 Bero 15,050 105 69.8 0 0.0 0 0.0 0 0.0 105 69.8 
13 Guraferda 43,311 663 153.1 12 2.8 4 0.9 0 0.0 679 156.8 
South Omo 14 South Ari 258,552 2,277 88.1 41 1.6 101 3.9 42 1.6 2,461 95.2 
SNNP regional total 1,764,654 16,690 94.6 284 1.6 239 1.4 72 0.4 17,285 98.0 
Amhara 
Awi 
15 Zigem 82,174 1,203 146.4 34 4.1 23 2.8 2 0.2 1,262 153.6 
16 Guanga ǂ 191,738 1,487 77.6 38 2.0 54 2.8 3 0.2 1,582 82.5 
South Gondor 
17 Ebinat ǂ 270,365 1,080 39.9 112 4.1 6 0.2 0 0.0 1,198 44.3 
18 Fogera ǂ 280,522 1,932 68.9 72 2.6 31 1.1 0 0.0 2,035 72.5 
19 Simada 280,304 1,033 36.9 157 5.6 10 0.4 0 0.0 1,200 42.8 
East Gojam 20 E/Enawga ǂ 205,560 1,483 72.1 53 2.6 24 1.2 0 0.0 1,560 75.9 
Amhara regional total  1,310,663 8,218 62.7 467 3.6 148 1.1 5 0.04 8,838 67.4 
Overall total 3,075,318 24,908 81.0 751 2.4 387 1.3 77 0.3 26,123 84.9 
* Hydrocoele prevalence based on total population  
** Both refers to patients identified as having both hydrocoele and lymphoedema conditions 
ǂ Remapping indicated that these districts were non-endemic [14] 
 
 12 
In terms of clinical conditions, the total number of cases reported comprised of 24,908 (95.3%) 224 
leg lymphoedema, 751 (2.9%) hydrocoele, 387 (1.5%) both leg lymphoedema and hydrocoele, and 77 225 
(0.3%) breast lymphoedema. No individual patient was reported as having both a breast 226 
lymphoedema and a leg lymphoedema, and from this point onwards, the term ‘both conditions’ refers 227 
to a patient having both a leg lymphoedema and a hydrocoele.  The maps shown in Fig 1 A-H highlight 228 
the case and prevalence distributions across the study area. The districts with the highest number of 229 
cases were Sodo Zuria district, Wollaita zone (n=2,581), and South Ari district, South Omo zone 230 
(n=2,461) of the SNNPR (Table 1). The districts with the lowest number of cases were Bero district, 231 
Bench Maji zone (n=105), and Saula Town, GamoGofa zone (n=248) of the SNNPR. The distribution of 232 
all cases by district is shown in Fig 1 A.  233 
Overall, the morbidity prevalence rate was 84.9 per 10,000 total population (Table 1). T; for 234 
the SNNPR rate of it was 98.0 per 10,000 was significantly higher than the , and for Amhara region 235 
rate of was 67.40 per 10,000 (OR 1.46; 95%CIs 1.42-1.50; P< 0.0001). The districts with the highest 236 
prevalence rates were Gezegofa district (164.7 per 10,000), and Oyida district (158.7 per 10,000) in 237 
the GamoGofa zone of the SNNPR, while the district with the lowest was Hawela Tula district, Sidama 238 
zone (26.8 per 10,000) of the SNNPR. The distribution of all cases is shown in Fig 1 B. When comparing 239 
by endemicity status, the overall prevalence rate in the non-endemic districts of 70.6 per 10,000 was 240 
significantly lower than the endemic districts (96.1 per 10,000) (OR 0.73; CIs 0.71-0.75; P<0.0001). 241 
The density of cases overall was 17.53 cases per km2 (see S1 Table).  The SNNPR (23.6 cases 242 
per km2) had a higher density of cases than the Amhara region (11.66 cases per km2). The highest 243 
district level density of cases were in the urban areas, Saula Town, GamoGofa zone (634 per km2) of 244 
the SNNPR, and Zigem, Awi zone (467 per km2) of the Amhara region. The lowest density of cases were 245 
in Bero district (2.18 cases per km2), and Guraferda district (3.35 cases per km2) of the Bench Maji zone 246 
of the SNNPR. 247 
 248 
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Lymphoedema cases 249 
Summary. Overall, leg lymphoedema (only) accounted for most of the cases reported and was found 250 
in similar patterns to the total number of cases and prevalence rates described above and shown in 251 
Table 1. The districts with the highest number of cases were Sodo zuria district, Wollaita zone 252 
(n=2,564), and the lowest was Bero district, Bench Maji zone (n=105) of the SNNPR. Similarly, the 253 
overall lymphoedema prevalence rate was 81.0 per 10,000 total population. T; for the SNNPR rate of 254 
it was 94.6 per 10,000 was significantly higher than the Amhara region rate of and 62.7 per 10,000 255 
(OR 1.51; 95%CIs 1.47-1.55; P< 0.0001) for Amhara region. The district with the highest prevalence 256 
rate was Gezegofa district, GamoGofa zone (159.3 per 10,000), and the lowest was Hawela Tula 257 
district, Sidama zone (26.5 per 10,000) of the SNNPR. When comparing by endemicity status, the 258 
lymphoedema prevalence rate in the non-endemic districts of 66.8 per 10,000 was significantly lower 259 
than the endemic districts (92.1 per 10,000) (OR 0.73; CIs 0.71-0.74; P<0.0001). In addition, similar 260 
trends in the density of lymphoedema cases was found as the overall total as shown in S1 Table 1. 261 
Overall, more females (54.2%; n=13,495) reported leg lymphoedema (only) than males. The 262 
majority of cases were aged above 30 years of age, with similar patterns for both males and females. 263 
The distribution of leg lymphoedema by age and sex is shown in Fig 2 A.  A small number of male cases 264 
reported having both a leg lymphoedema and a hydrocoele (n=387) in 18 of the 20 districts. A smaller 265 
number of females reported having breast lymphoedema (n=77) in 7 of the 20 districts, with most 266 
recorded in South Ari district, South Omo zone (n=42) and Boreda district, GamaGofa zone (n=25) of 267 
the SNNPR (Table 1). The distribution of breast lymphoedema and hydrocoele cases by age and sex is 268 
shown in Fig 2 B.   269 
 270 
Fig 2. Number of leg lymphoedema, breast lymphoedema and hydrocoele cases by sex and age. A. 271 
Leg lymphoedema. B. Breast lymphoedema and hydrocoele 272 
 273 
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 274 
Number of limbs affected by leg lymphoedema. In total, 25,295 cases reported leg 275 
lymphoedema, including those with leg lymphoedema (only), and those with both leg lymphoedema 276 
and hydrocoele. Of these, 89.3% (n=22,597) reported they had bilateral leg lymphoedema with similar 277 
percentages found in both the SNNPR (89.9%) and Amhara region (88.1%). More variation at district 278 
level was reported with the percentage of bilateral leg lymphoedema cases ranging from 80.2% to 279 
96.1%. The number and distribution of unilateral and bilateral cases by district are summarised in 280 
Table 2 and shown in Fig 1 A, C, E.  281 
 282 
Table 2. Reported number, prevalence (per 10,000 of the total population) and ratio of unilateral 283 
and bilateral cases of leg lymphoedema.284 
 15 
Region Zone District 
Total 
population 
Leg lymphoedema*  
Bilateral 
% of total 
Unilateral: 
bilateral  
ratio (n) 
Unilateral Bilateral 
Total 
N Prevalence N Prevalence  
SNNPR 
Siliti 
Lanfuro 142,581 186 13.0 1,598  112.1  1,784 89.6% 1: 9 
Sankura 104,051 116 11.1 1,031  99.1  1,147 89.9% 1: 9 
Sidama 
Hawela Tula 152,844 16 1.0 390  25.5  406 96.1% 1: 24 
Bensa ǂ 307,878 379 12.3 1,532  49.8  1,911 80.2% 1: 4 
Gedeo Yirga Chefe 239,763 77 3.2 1,635  68.2  1,712 95.5% 1: 21 
Wollaita Sodo zuria 199,775 245 12.3 2,324  116.3  2,569 90.5% 1: 9 
GamoGofa 
Boreda 83,451 123 14.7 961  115.2  1,084 88.7% 1: 8 
Gezegofa 84,298 93 11.0 1,282  152.1  1,375 93.2% 1: 14 
Oyida 40,903 54 13.2 588  143.8  642 91.6% 1: 11 
Saula Town ǂ 27,879 13 4.7 234  83.9  247 94.7% 1: 18 
Gurage Kebena ǂ 64,318 138 21.5 764  118.8  902 84.7% 1: 6 
Bench Maji 
Bero 15,050 9 6.0 96  63.8  105 91.4% 1: 11 
Guraferda 43,311 60 13.9 607  140.1  667 91.0% 1: 10 
South Omo South Ari 258,552 193 7.5 2,185  84.5  2,378 91.9% 1: 11 
SNNP regional total 1,764,654 1,702 9.6 15,227 86.3 16,929 89.9% 1: 9 
Amhara 
Awi 
Zigem 82,174 113 13.8 1,113  135.4  1,226 90.8% 1: 10 
Guanga ǂ 191,738 81 4.2 1,460  76.1  1,541 94.7% 1: 18 
South Gondor 
Ebinat ǂ 270,365 190 7.0 896  33.1  1,086 82.5% 1: 5 
Fogera ǂ 280,522 212 7.6 1,751  62.4  1,963 89.2% 1: 8 
Simada 280,304 184 6.6 859  30.6  1,043 82.4% 1: 5 
East Gojam E/Enawga ǂ 205,560 216 10.5 1,291  62.8  1,507 85.7% 1: 6 
Amhara regional total 1,310,663 996 7.6 7,370 56.2 8,366 88.1% 1: 7 
Overall total 3,075,318 2,698 8.8 22,597 73.5 25,295 89.3% 1: 8 
*Leg lymphoedema including those with leg lymphoedema only and both conditions (lymphoedema and hydrocele) 
ǂ Remapping indicated that these districts were non-endemic [14] 
  
285 
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The overall ratio of unilateral to bilateral leg lymphoedema cases was 1:8, which was similar 286 
between the SNNPR (1:9) and Amhara region (1:7). Similarly, there was more variation at district level 287 
with ratios ranging from 1:4 to 1:24, with the highest reported in Hawela Tula district, Sidama zone 288 
(1:24) and Yirga Chefe district, Gedeo zone (1:21) and the lowest in Bensa district, Sidama zone of the 289 
SNNPR (1:4).  290 
Similarly, the overall prevalence of unilateral (8.8 per 10,000) and bilateral (73.5 per 10,000) 291 
lymphoedema cases differed, with similar large differences between unilateral and bilateral leg 292 
lymphoedema within each region. When comparing between regions, a significantly higher 293 
prevalence of unilateral lymphoedema was reported in the SNNPR (9.6 per 10,000) compared with 294 
Amhara region (7.6 per 10,000) (OR 1.27; CIs 1.17-1.37; P<0.0001). Similarly, a significantly higher 295 
prevalence of bilateral lymphoedema was reported in the SNNPR (86.3 per 10,000) compared with 296 
Amhara region (56.2 per 10,000) (OR 1.54; CIs 1.50-1.58; P<0.0001), however this was not found to 297 
be significantly different. The overall prevalence and distribution of all, unilateral and bilateral cases 298 
are summarised in Table 2 and shown in Fig 1 B, D, F. 299 
 300 
Severity of leg lymphoedema. The number of cases (n=25,295) reporting mild, moderate or severe 301 
leg lymphoedema (including those with leg lymphoedema only and both leg lymphoedema and 302 
hydrocoele) varied significantly (chi square <0.05). Over half of the cases were recorded as mild 303 
(57.8%; n=14,492), approximately one third as moderate (33.8%; n=8,538) and 9% as severe (n=2,265). 304 
The proportion of male and female cases for each stage was similar, with just over half of mild, 305 
moderate and severe cases being female; 54.1%, 52.6% and 51.6%, respectively.   306 
In terms of age, significant differences were found in the mean age and the different stages 307 
of leg lymphoedema, with an increasing trend in the severity of the condition by age group. The mean 308 
age of cases reporting mild, moderate and severe leg lymphoedema was 45.1 years (95% CI 44.8-45.3), 309 
47.6 years (95% CI 47.3-47.9) and 49.0 years (95% CI 48.3-49.6) respectively. 310 
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  311 
 312 
Hydrocoele cases 313 
In all 20 districts, the total number and prevalence of men reporting hydrocoele was low with 314 
only 751 cases reported overall and a prevalence of 2.4 per 10,000 population (Table 1). T; the SNNPR 315 
rates of (n=284; 1.6 per 10,000) was had a significantly lower number of cases and prevalence than 316 
the Amhara region rates of (n=467; 3.6 per 10,000 (OR 0.45; 95%CIs 0.39-0.52; p< 0.0001). The two 317 
districts with the highest number of cases and prevalence rates were Simada district (n=157; 5.6 per 318 
10,000), and Ebinat district (n=112; 4.1 per 10,000), South Gondor zone in Amhara region. Of note 319 
Ebinat district was recently re-classified as ‘non-endemic’ for LF [14]. Bero district, Bench Maji zone in 320 
the SNNPR reported no cases.  All reported cases of hydrocoele were male with the majority aged 41 321 
to 60 years (41.9%; n=315) The number of cases reported increased with age as highlighted in Fig 2 B.  322 
When comparing by endemicity status, the hydrocoele prevalence rate in the non-endemic districts 323 
of 2.7 per 10,000 was significantly higher than the endemic districts of 2.3 per 10,000) (OR 1.2; CIs 1.0-324 
1.4; P=0.029). 325 
The density of hydrocoele cases overall was very low at 0.5 cases per km2 (see S1 Table).  The 326 
SNNPR (0.39 cases per km2) had a lower density of cases than the Amhara region (0.62 cases per km2). 327 
The highest district level density of cases were in the urban areas, Saula Town, GamoGofa zone (2.56 328 
cases per km2) of the SNNPR, and Zigem, Awi zone (12.58 cases per km2) of the Amhara region. The 329 
lowest density of cases was in Guraferda district (0.06 cases per km2), Bench Maji zone of the SNNPR. 330 
 331 
Acute attacks 332 
Of all the 26,123 cases identified, a total of 1,931 cases did not record any reliable information 333 
on acute attacks in the last six months, and therefore were excluded from this analysis (Table 3). Of 334 
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the 24,192 cases with information recorded, approximately two-thirds (64.1%; n=15,517/24,192) 335 
reported that they had at least one acute attack in the last six months due to their 336 
swelling/lymphoedema. Similar proportions were recorded for those with leg lymphoedema (64.5%; 337 
n=14,935/23,165), and/or both conditions (65.3%; n=211/323). Men with hydrocoele (54.5%; 338 
n=343/629) and women with breast lymphoedema (37.3%; n=28/75) reported fewer acute attacks. 339 
 340 
 341 
 342 
 343 
 344 
Table 3. Reported acute attacks for all conditions by different age groups and by sex. 345 
                           Overall                                          Differences by sex 
Age 
group 
Total   
cases 
No. 
Positive 
(%) 
Sex 
Subtotal 
(n) 
Total positive 
Positive 
% 
Age - sex 
OR (95% CI) 
P value 
<20 974 
549 
(56.4%) 
M 368 185 50.3% 1.49 
(1.15-1.93) 
0.0029* 
F 606 364 60.1% 
20-29 1,969 
1,155 
(58.7%) 
M 756 416 55.0% 1.27 
(1.06-1.53) 
0.0098* 
F 1,213 739 60.9% 
30-39 4,803 
2,911 
(60.6%) 
M 2,068 1,199 58.0% 1.21 
(1.07-1.36) 
0.0012* 
F 2,735 1,712 62.6% 
40-49 5,865 
3,723 
(63.5%) 
M 2,732 1,668 61.1% 1.21 
(1.09-1.35) 
0.0003* 
F 3,133 2,055 65.6% 
50-59 4,921 
3,220 
(65.4%) 
M 2,318 1,459 62.9% 1.23 
(1.09-1.39) 
0.0005* 
F 2,603 1,761 67.7% 
>60 5,660 
3,959 
(69.9%) 
M 3,308 2,285 69.1% 1.11 
(0.98-1.24) 
0.0898 
F 2,352 1,674 71.2% 
Total 24,192 
15,517 
(64.1%) 
M 11,550 7,212 62.4% 1.13 
(1.07-1.19) 
<0.0001* 
F 12,642 8,305 65.7% 
A total of 1,931 participants did not record information on acute attacks and therefore were excluded from the 346 
analysis. In the table, positive refers to patients who reported experiencing at least one acute attack in the last 347 
six months.  348 
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* Statistically significant at <0.05 349 
 350 
Overall, a higher percentage of females reported they had an acute attack in the last six 351 
months (65.7%; n=8,305/12,642) than males (62.4%; n=7,212/11,550), this was a significant difference 352 
(OR 1.13; 95%Cis 1.07-1.19) (Table 3). Overall, the percentage of acute attacks increased with age, 353 
which was similar for both males and females (Fig 3 A). The lowest percentage of acute attacks 354 
reported were in the <20 year age group (56.4%) and the highest in the older >60 year age group 355 
(69.9%). A significantly higher percentage of females reported acute attacks than males across all age 356 
groups; an exception to this was the >60 year age group as shown in Table 3.   357 
 358 
 359 
Fig 3. Proportion of cases experiencing acute attacks by age group and severity of lymphoedema 360 
stratified by sex. A. Age group. B. Severity of lymphoedema 361 
 362 
In terms of severity of leg lymphoedema, a total of 23,488 cases had information recorded 363 
(Table 4). Overall, the percentage of acute attacks reported increased with the severity of the 364 
condition; mild (62.8%; n=8,529), moderate (65.2%; n=5,111) and severe (72.5%; n=1,506) as shown 365 
in Fig 3 B. A significantly higher percentage of females reported acute attacks with mild (OR 1.17; 366 
95%Cis 1.10-1.26) and moderate (OR 1.12; 95%Cis 1.02-1.23) conditions than males, however no 367 
difference by sex was found with severe conditions. 368 
 369 
Table 4. Reported leg lymphoedema severity and acute attacks of reported cases. 370 
Severity 
 
Overall Differences by sex 
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Total 
cases 
No. 
positive 
(%) 
   Sex 
 Subtotal 
       (n) 
Total positive 
Positive 
% 
OR (95% CI) P value 
Mild 13,577 
8,529 
(62.8%) 
M 6223 3780 60.7% 1.17 
(1.10 - 1.26) 
<0.0001* 
F 7354 4749 64.6% 
Moderate 7,833 
5,111 
(65.2%) 
M 3698 2361 63.8% 1.12 
(1.02-1.23) 
0.0136* 
F 4135 2750 66.5% 
Severe 2,078 
1,506 
(72.5%) 
M 1000 728 72.8% 0.97 
(0.80 – 1.17) 
0.748 
F 1078 778 72.2% 
Total 23,488 
15,146 
(64.5%) 
M 10921 6869 62.9% 1.14 
(1.08 – 1.20) 
<0.0001* 
F 12567 8277 65.9% 
Leg lymphoedema included those cases reporting leg lymphoedema only and both conditions. In total 1,807 371 
cases of 25,295 total number were excluded from the analysis as they did not record information on acute 372 
attacks. In the table, positive refers to patients who reported experiencing at least one acute attack in the last 373 
six months. 374 
* Statistically significant at <0.05 375 
 
Discussion 376 
This study represents the first community-wide integrated clinical case survey of both LF and 377 
podoconiosis in Ethiopia. In the 2007 epidemiological mapping of LF in 112 districts of Western 378 
Ethiopia, only advanced cases of LF-related lymphoedema elephantiasis and hydrocoele were only 379 
reported from selected villages within the surveyed districts [17]. Later, during the integrated 380 
endemicity mapping in 658 districts in 2013, clinical cases of LF and podoconiosis had only been 381 
reported from two kebeles per district using a two-stage cluster purposive sampling strategy [18, 19]. 382 
Other studies assessing the clinical burden of either LF or podoconiosis individually have generally only 383 
been conducted at a smaller geographical scale, and only in districts known to be endemic for the 384 
specific disease [22-27].  385 
The present survey results highlight a greater burden of lymphoedema cases compared to 386 
that of hydrocoele, with over 33 times as many leg lymphoedema cases reported than hydrocoele. 387 
These results differ to other studies on clinical case estimates in African LF-endemic areas ofcountries 388 
 21 
including Malawi, Ghana,  and Tanzania where the number of hydrocoele cases identified was almost 389 
double that of lymphoedema cases identified [28, 29].Bangladesh [28-30], butThis is likely to be 390 
related to the presence of podoconiosis in Ethiopia. Here we highlight that the vast majority of 391 
lymphoedema cases were bilateral; a manifestation more typically seen with non-filarial 392 
lymphoedema elephantiasis [9]. Although these results suggest that a clear majority of lymphoedema 393 
cases identified are likely to be caused by podoconiosis rather than filariasis, this present study did 394 
not distinguish between the causes of lymphoedema.  These results are supported by previous 395 
findings by Deribe et al [31], which highlights the huge burden of podoconiosis in the SNNP and 396 
Amhara regions of Ethiopia, particularly in the central highland area where distinct environmental and 397 
climatic factors are suitable for podoconiosis occurrence.. LF tests including circulating filarial antigen 398 
testing, filarial antibody examination and parasitological examination have been used to exclude an 399 
LF diagnosis in other studies in LF and podoconiosis co-endemic areas [32], but for the purposes of 400 
understanding the burden of lymphoedema to establish MMDP interventions in this study, a detailed 401 
understanding of aetiology was not required as the same MMDP interventions are required for both 402 
filarial and non-filarial lymphoedema.  403 
Regardless of aetiology, the high number of leg lymphoedema cases highlights the pressing 404 
need to deliver a basic package of care to those suffering from these disabling conditions, especially 405 
in areas with a high prevalence and/or high density of conditions where patients may be more readily 406 
found and the distribution of care easier. The delivery of a low-cost lymphoedema management 407 
programme based on limb washing and topical medication for infection has been shown to reduce the 408 
number of debilitating acute attacks and to increase the economic productivity of patients [33]. An 409 
integrated MMDP programme will help the majority of lymphoedema cases in these districts as most 410 
were identified as having a mild severity and are likely to respond well to such treatment [34]. Such 411 
an MMDP programme should be fully integrated into the existing health system structure to ensure 412 
sustainability and help achieve universal health coverage. It should also promote early detection of 413 
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mild lymphoedema cases, which may be underreported by HEWs, to prevent progression to a more 414 
severe stage of lymphoedema.  415 
A verification exercise to confirm reported cases of lymphoedema and hydrocele by a clinician 416 
has been used in other studies to validate the reporting method used for patient searching [14, 29], 417 
but due to financial and time constraints, was not included in this study. Such verification exercises 418 
have evidenced that community health workers are exceptionally well-placed to participate in 419 
quantifying LF morbidity burden, and other NTDs with observable symptoms [29], such as 420 
podoconiosis. As other countries begin to develop their own methods for obtaining patient estimates 421 
to achieve the second component of the GPELF strategy, this study has highlighted that integrated 422 
patient searching using community health workers is an effective strategy. By including two diseases, 423 
this method is cost-effective and empowers local health workers to contribute to local, national and 424 
global elimination of disease. 425 
In this study, those with more severe disease were shown to be more likely to have 426 
experienced an acute attack in the past six months. This is not a surprising result as the presence of 427 
moisture, which commonly accumulates in swollen folds of skin, or the web spaces of toes during 428 
lymphoedema promotes fungal infections, leading to an acute attack [35-37]. Also, older age groups 429 
were shown to have a more severe stage of disease, were more likely to have bilateral lymphoedema, 430 
and were more likely to have experienced an acute attack in the past six months. As lymphoedema is 431 
a chronic, progressive condition, this is to be anticipated and highlights the important need to 432 
implement an accessible package of care to all lymphoedema patients to prevent the progression of 433 
their condition to a more disabling and debilitating severe stage.  434 
The low number of hydrocoele cases identified in this study further suggests that LF is of low 435 
prevalence in these regions of Ethiopia, and that with well-targeted morbidity strategies, GPELF 436 
targets could be reached. However, it is important to consider that as hydrocoele is a highly 437 
stigmatised condition [38], the numbers reported in this study could be an underestimation. As HEWs 438 
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are predominately female and likely to be from the same community as the patient [20], some patients 439 
may not have disclosed their condition to their HEW. For thosee hydrocoele cases identified in this 440 
study and those that may remain hidden, it is important to identify equitable ways to refer and 441 
facilitate access to safe hydrocoele surgery to repair their condition. In an effort to support this, 442 
international partners have worked together with the Federal Ministry of Health (FMOH) to develop 443 
a hydrocoele surgical handbook and trained regional surgeons across Ethiopia on surgical best practise 444 
[39]. Such surgery has been shown to positively impact patients’ lives, improving their physical and 445 
socio-economic output [40] and to be highly cost-effective [41]. Facilitating access to surgery in the 446 
districts now classified as ‘non-endemic’ will be particularly important as patients could miss out on 447 
treatment if resources are not prioritised to these districts, especially as the prevalence rates were 448 
higher than the endemic districts. However, it will still remain important to provide services for 449 
lymphoedema patients in these regions also, whether they are caused by LF or podoconiosis.  450 
In order to achieve the second pillar of the GPELF plan, services to alleviate the suffering of 451 
clinical disease needs to be available within primary health care systems in all areas of known patients 452 
[42]. The results of this As this study highlights the profound burden of clinical disease, particularly 453 
lymphoedema., Since 2015, funds have been mobilised by the Centre for Neglected Tropical Diseases 454 
at the Liverpool School of Tropical Medicine (LSTM) with funding from the Department for 455 
International Development (UKAID) to provide lymphoedema and hydrocele patients across all 20 456 
districts with access to care.further understanding of the local situation and additional funding are 457 
now essential to reduce the associated morbidity, especially in very high risk areas i.e. morbidity 458 
hotspots. The results of this study se advancements will have therefore helped to improve the 459 
management of both LF and podoconiosis morbidity, understand the geographical burden and will 460 
assist the NTD programme in Ethiopia to achieveing elimination goals.  461 
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